Skip to main content

LeonaBio, Inc.

corporate_fare Company Profile

LeonaBio, Inc.

LONA·NASDAQ·Life Sciences·CIK 0001620463

LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for significant unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). In December 2025, the company acquired rights to lasofoxifene, a late-stage asset for the potential treatment of ESR1-mutated (mESR1) metastatic breast cancer. This program has generated promising clinical data. LeonaBio, Inc. also has an in-house asset, ATH-1105, which is a Phase 2-ready program for the potential treatment of ALS. The company aims to advance a pipeline of innovative, late-stage assets, both internally developed and strategically in-licensed. LeonaBio, Inc.'s lead drug candidates are lasofoxifene and ATH-1105, which are novel, small molecule therapies. Lasofoxifene, a selective estrogen receptor modulator (SERM), is currently being evaluated in an ongoing registrational Phase 3 trial for metastatic breast cancer with ESR1 mutations. ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, has completed a first-in-human Phase 1 trial, and planning for a Phase 2 clinical trial for the treatment of ALS is underway. These programs target unmet needs in either oncology or neurology.

LeonaBio, Inc. (NASDAQ:LONA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for LONA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for LONA spans 10-Q, 8-K, SCHEDULE 13D, DEF 14A.

Recent high-impact activity:

  • LeonaBio Q3 Cash Falls to $32.3M; Going Concern Warning Reiterated
  • Cash Falls to $32.3M as Q3 Net Loss Widens to $21.2M; ELAINE-3 Enrollment Slips to 4Q 2026
  • LeonaBio's 23M Series A Warrants Now Exercisable, Potential $146.2M Cash Inflow
  • Sermonix Exercises 3.15M Warrants, Distributes 4.73M LeonaBio Shares
  • LeonaBio Reaches 500th Patient in Phase 3 ELAINE-3, Opening $146M Warrant Exercise Window

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$105.61M
Diluted EPS
-$24.70
Op. Cash Flow
-$45.73M
Operating Income
-$102.27M
Cash & Equivalents
$69.28M
Debt / Equity
0.00×
Shares Outstanding
9.34M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134565

Short Interest & Short Volume

1.13 days to cover

FINRA reported short interest of 74,491 shares in LONA as of the October 30, 2026 settlement, a 14.7% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of LONA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)74,491 shares as of October 30, 2026
Change vs prior period▼ 14.7%
Days to cover1.13 at avg daily volume of 65,795
Daily short volume (FINRA facilities)43.1% of 20,188 shares on November 20, 2026
5-day average short volume44.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$2.01 -0.50% today
52-week range · as of 2026-11-16 $2.01 – $14.21
Market cap
$26.41M
Volume
68.9K (1.0× avg)
3-mo avg 71.6K
Live data · 2026-11-22 01:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LONA - Latest Insights

LONA
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.23
Real-time Price: $2.01 info
Change: -$1.22 (-38%) info
Market Cap: $26.414M info
LONA
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.23
Real-time Price: $2.01 info
Change: -$1.22 (-38%) info
Market Cap: $26.414M info
LONA
Sep 22, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $2.01 info
Change: -$4.04 (-67%) info
Market Cap: $26.414M info
LONA
Aug 31, 2026, 4:31 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $7.92
Real-time Price: $2.01 info
Change: -$5.91 (-75%) info
Market Cap: $26.414M info
LONA
Aug 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.01
Real-time Price: $2.01 info
Change: -$6.00 (-75%) info
Market Cap: $26.414M info
LONA
Aug 14, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.97
Real-time Price: $2.01 info
Change: -$5.96 (-75%) info
Market Cap: $26.414M info
LONA
Aug 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.97
Real-time Price: $2.01 info
Change: -$5.96 (-75%) info
Market Cap: $26.414M info
LONA
May 11, 2026, 4:45 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $10.01
Real-time Price: $2.01 info
Change: -$8.00 (-80%) info
Market Cap: $26.414M info
LONA
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $2.01 info
Change: -$7.74 (-79%) info
Market Cap: $26.414M info
LONA
May 07, 2026, 4:19 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $9.75
Real-time Price: $2.01 info
Change: -$7.74 (-79%) info
Market Cap: $26.414M info
LONA
May 07, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $9.75
Real-time Price: $2.01 info
Change: -$7.74 (-79%) info
Market Cap: $26.414M info
LONA
Apr 01, 2026, 9:30 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $10.12
Real-time Price: $2.01 info
Change: -$8.11 (-80%) info
Market Cap: $26.414M info
LONA
Apr 01, 2026, 9:30 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $2.01 info
Change: -$8.11 (-80%) info
Market Cap: $26.414M info
LONA
Mar 31, 2026, 5:07 PM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $2.01 info
Change: -$8.07 (-80%) info
Market Cap: $26.414M info
LONA
Mar 31, 2026, 4:59 PM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $2.01 info
Change: -$8.07 (-80%) info
Market Cap: $26.414M info
LONA
Mar 31, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $10.28
Real-time Price: $2.01 info
Change: -$8.27 (-80%) info
Market Cap: $26.414M info
LONA
Mar 31, 2026, 2:20 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $10.07
Real-time Price: $2.01 info
Change: -$8.06 (-80%) info
Market Cap: $26.414M info
LONA
Mar 26, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.68
Real-time Price: $2.01 info
Change: -$7.67 (-79%) info
Market Cap: $26.414M info
LONA
Mar 26, 2026, 5:10 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $9.68
Real-time Price: $2.01 info
Change: -$7.67 (-79%) info
Market Cap: $26.414M info
LONA
Mar 19, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.45
Real-time Price: $2.01 info
Change: -$8.44 (-81%) info
Market Cap: $26.414M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets